All Stories

  1. Parkinson's Disease and Retinal Age Gap: A Cross‐Sectional Analysis
  2. Corneal confocal microscopy as a paraclinical test in neurodegenerative disease: a scoping review
  3. Treatment of post-vaccination optic neuritis: implications from the global SARS-CoV-2 vaccination effort
  4. From anatomical and functional observations to molecular dynamics in internal limiting membrane peeling
  5. Proteolysis‐Based Biomarker Repertoire of the Neurofilament Proteome
  6. Methanol toxicity; characteristics, ophthalmological sequelae and recommended treatment
  7. Macular, choroidal and disc associations across women’s reproductive life stages: a scoping review from menarche to post-menopause
  8. Validation of the 2023 International Diagnostic Criteria for MOGAD in a Selected Cohort of Adults and Children
  9. How far should I manage acute optic neuritis as an ophthalmologist? A United Kingdom perspective
  10. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis
  11. Interpretation of composite OCT/MRI findings: a clinical review of retinotopy
  12. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease
  13. Partial Parallelism Plots
  14. Exploring Vitreous Haze as a Potential Biomarker for Accelerated Glymphatic Outflow and Neurodegeneration in Multiple Sclerosis: A Cross-Sectional Study
  15. Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial
  16. Correction: NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies
  17. NAION or not NAION? A literature review of pathogenesis and differential diagnosis of anterior ischaemic optic neuropathies
  18. Reply: Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation
  19. Peripherin is a biomarker of axonal damage in peripheral nervous system disease
  20. The Association of Alcohol Consumption with Glaucoma and Related Traits
  21. Differentiating glaucoma from chiasmal compression using optical coherence tomography: the macular naso-temporal ratio
  22. Remodeling of the neuromuscular junction in myasthenia gravis increases serum neurofilament heavy chain levels
  23. Application of diagnostic criteria for optic neuritis – Authors' reply
  24. Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort
  25. Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders
  26. Correction: UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
  27. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
  28. Applying a genetic risk score model to enhance prediction of future Multiple Sclerosis diagnosis at first presentation with optic neuritis: a cohort study in the UK Biobank
  29. A novel eye-movement impairment in multiple sclerosis indicating widespread cortical damage
  30. Diagnosis and classification of optic neuritis
  31. The Role of the Inner Nuclear Layer for Perception of Persisting Tiling Inside a Monocular Scotoma
  32. UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
  33. Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort
  34. Pattern ERGs suggest a possible retinal contribution to the visual acuity loss in acute optic neuritis
  35. The 2022 Lady Estelle Wolfson lectureship on neurofilaments
  36. The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis
  37. Automated detection of hyperreflective foci in the outer nuclear layer of the retina
  38. The Association between Serum Lipids and Intraocular Pressure in 2 Large United Kingdom Cohorts
  39. The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis
  40. Artificial intelligence enabled retinal vasculometry for prediction of circulatory mortality, myocardial infarction and stroke
  41. Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MS
  42. Author Correction: Seven day pre-analytical stability of serum and plasma neurofilament light chain
  43. Sub-cellular level resolution of common genetic variation in the photoreceptor layer identifies continuum between rare disease and common variation
  44. Associations of Alcohol Consumption and Smoking With Disease Risk and Neurodegeneration in Individuals With Multiple Sclerosis in the United Kingdom
  45. AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK
  46. Neuro-Ophthalmic Implications of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Related Infection and Vaccination
  47. Blood GFAP as an emerging biomarker in brain and spinal cord disorders
  48. Upregulated Retinal Neurofilament Expression in Experimental Optic Neuritis
  49. Clinical review of retinotopy
  50. Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study
  51. Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics
  52. Dynamic volume‐rendered optical coherence tomography pupillometry
  53. Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox
  54. Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders
  55. Myelin-oligodendrocyte glycoprotein antibody-associated disease
  56. Update on Optic Neuritis: An International View
  57. APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies
  58. Re-evaluating diabetic papillopathy using optical coherence tomography and inner retinal sublayer analysis
  59. Seven day pre-analytical stability of serum and plasma neurofilament light chain
  60. Artificial intelligence extension of the OSCAR‐IB criteria
  61. Three “Red Lines” for Pattern Recognition-Based Differential Diagnosis Using Optical Coherence Tomography in Clinical Practice
  62. Investigation of associations between retinal microvascular parameters and albuminuria in UK Biobank: a cross-sectional case-control study
  63. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries
  64. Peripapillary Hyper-reflective Ovoid Mass-like Structure (PHOMS): An Optical Coherence Tomography Marker of Axoplasmic Stasis in the Optic Nerve Head
  65. A model for interrogating the clinico‐radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia
  66. Reply to “Peripapillary Hyper‐Reflective Ovoid Masslike Structures in Astronauts”
  67. Relationships between retinal layer thickness and brain volumes in the UK Biobank cohort
  68. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
  69. Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain network
  70. Optical Coherence Tomography Angiography (OCTA) in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
  71. Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease
  72. Retinal asymmetry in multiple sclerosis
  73. Optical coherence tomography (OCT) in neuro-ophthalmology
  74. Serum neurofilament light chain withstands delayed freezing and repeated thawing
  75. Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis
  76. Comment on: Morphologic Features of Buried Optic Disc Drusen on En Face Optical Coherence Tomography and Optical Coherence Tomography Angiography
  77. Young Adults With Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study
  78. Multirater Validation of Peripapillary Hyperreflective Ovoid Mass-like Structures (PHOMS)
  79. Acute Disseminated Encephalomyelitis with Seizures and Myocarditis: A Fatal Triad
  80. Automated Pupillometry Using a Prototype Binocular Optical Coherence Tomography System
  81. Blocked Eye-Brain connection in Multiple Sclerosis
  82. Ambient Air Pollution Associations with Retinal Morphology in the UK Biobank
  83. Biomarker Panel to Differentiate Brain Injury From Brain Dysfunction in Patients With Sepsis-Associated Encephalopathy
  84. Weighting evidence in MS: Obesity and neurodegeneration
  85. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD
  86. Vision Loss from Atypical Optic Neuritis: Patient and Physician Perspectives
  87. Genome-wide association meta-analysis of corneal curvature identifies novel loci and shared genetic influences across axial length and refractive error
  88. Anterior visual system imaging to investigate energy failure in multiple sclerosis
  89. Saccadic delay in multiple sclerosis: A quantitative description
  90. Can stability of visual fixation be a measure for disability in multiple sclerosis?
  91. Protein aggregate formation permits millennium-old brain preservation
  92. A conscious rethink: Why is brain tissue commonly preserved in the archaeological record? Commentary on: Petrone P, Pucci P, Niola M, et al. Heat-induced brain vitrification from the Vesuvius eruption in C.E. 79. N Engl J Med 2020;382:383-4. DOI: 10.10...
  93. Comparison of Associations with Different Macular Inner Retinal Thickness Parameters in a Large Cohort
  94. Associations with photoreceptor thickness measures in the UK Biobank
  95. Neuro-Ophthalmic Literature Review
  96. Multi-trait genome-wide association study identifies new loci associated with optic disc parameters
  97. Time is Vision
  98. Associations with Corneal Hysteresis in a Population Cohort
  99. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients
  100. Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis
  101. Patterns of retrograde axonal degeneration in the visual system
  102. Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study
  103. Saccadic fatigability in the oculomotor system
  104. Progression of Anterograde Trans-Synaptic Degeneration in the Human Retina Is Modulated by Axonal Convergence and Divergence
  105. Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up
  106. Diagnosing and quantifying a common deficit in multiple sclerosis
  107. Quantile regression analysis reveals widespread evidence for gene-environment or gene-gene interactions in myopia development
  108. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study
  109. Quantification of Visual Fixation in Multiple Sclerosis
  110. Correction: The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study
  111. A 30 s test for quantitative assessment of a relative afferent pupillary defect (RAPD): the infrared pupillary asymmetry (IPA)
  112. Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double‐blind, placebo‐controlled cross‐over trial
  113. The relevance of buffer system ionic strength in immunoassay development
  114. Cohort profile: design and methods in the eye and vision consortium of UK Biobank
  115. The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy – A prospective, pilot observational study
  116. An ontological foundation for ocular phenotypes and rare eye diseases
  117. Retinal Asymmetry in Multiple Sclerosis
  118. Peripapillary Hyperreflective Ovoid Mass-Like Structures
  119. The International Multiple Sclerosis Visual System Consortium
  120. Association of Retinal Nerve Fiber Layer Thinning With Current and Future Cognitive Decline
  121. Peripapillary Ovoid Hyperreflectivity in Optic Disc Edema and Pseudopapilledema
  122. The role of optical coherence tomography and infrared oculography in assessing the visual pathway and CNS in multiple sclerosis
  123. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry
  124. Treating the Eyes to Help the Brain
  125. Neurofilaments as biomarkers in neurological disorders
  126. A standardized protocol for quantification of saccadic eye movements: DEMoNS
  127. Neuro-ophthalmic literature review
  128. Applying the 2017 McDonald diagnostic criteria for multiple sclerosis
  129. Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error
  130. The Pulfrich phenomenon: Practical implications of the assessment of cases and effectiveness of treatment
  131. Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy
  132. Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon
  133. Multicenter reliability of semiautomatic retinal layer segmentation using OCT
  134. Retinal optical coherence tomography shows optic disc changes in low intracranial pressure headaches: a case report
  135. Reply to the letter by Jasmin Zvorničanin on the article Prefoveal floaters as a differential diagnosis to optic neuritis: “mouches dormantes”
  136. Translational evidence for two distinct patterns of neuroaxonal injury in sepsis: a longitudinal, prospective translational study
  137. Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis
  138. The Optic Disc Drusen Studies Consortium Recommendations for Diagnosis of Optic Disc Drusen Using Optical Coherence Tomography
  139. Time is vision in recurrent optic neuritis
  140. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
  141. Biomarkers of Disease Progression
  142. Volume rendering of superficial optic disc drusen
  143. Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study
  144. Prefoveal floaters as a differential diagnosis to optic neuritis: “mouches dormantes”
  145. Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis
  146. Case 3-2017: A Man with Cardiac Sarcoidosis and New Diplopia and Weakness
  147. Optical coherence tomography angiography and retinal microvascular ramification in acute macular neuroretinopathy and paracentral acute middle maculopathy
  148. A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer
  149. Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers
  150. Neuroprotection and visual function after optic neuritis
  151. Biomarkers in Neurodegenerative Diseases
  152. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis
  153. Retinal glymphatic system: an explanation for transient retinal layer volume changes?
  154. An early case of a natural barrier to axonal degeneration
  155. Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study
  156. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies
  157. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study
  158. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study
  159. Plasma neurofilament heavy chain is not a useful biomarker in Charcot-Marie-Tooth disease
  160. Maintenance Intravenous Fluids in Acutely Ill Patients
  161. Autoimmunity in visual loss
  162. Elevated vitreous body glial fibrillary acidic protein in retinal diseases
  163. The prevalence of microcystic macular changes on optical coherence tomography of the macular region in optic nerve atrophy of non-neuritis origin: a prospective study
  164. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
  165. Cerebral Salt Wasting Syndrome
  166. Pain in Optic Perineuritis: Author Response
  167. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease
  168. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up
  169. Neuro-Ophthalmic Literature Review
  170. Diagnostic clues and manifesting carriers in fukutin-related protein (FKRP) limb-girdle muscular dystrophy
  171. The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid
  172. Visual pathway neurodegeneration winged by mitochondrial dysfunction
  173. Re: Garcia-Martin et al.: Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography (Ophthalmology 2014;121:573–9)
  174. Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration
  175. Neuro-Ophthalmic Literature Review
  176. Physiological variation of retinal layer thickness is not caused by hydration: A randomised trial
  177. Retinal Segmentation to Demonstrate Hyperplasia in Ataxia of Charlevoix-Saguenay: Critique on Study Methodology and Results
  178. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
  179. The investigation of acute optic neuritis: a review and proposed protocol
  180. Effects of Repeated Intrathecal Triamcinolone-Acetonide Application on Cerebrospinal Fluid Biomarkers of Axonal Damage and Glial Activity in Multiple Sclerosis Patients
  181. Serum lactate as a novel potential biomarker in multiple sclerosis
  182. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis
  183. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria
  184. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome
  185. Neuro-Ophthalmic Literature Review
  186. Cerebrospinal fluid transferrin levels are reduced in patients with early multiple sclerosis
  187. Diagnosis and classification of autoimmune optic neuropathy
  188. Current and future potential of retinal optical coherence tomography in multiple sclerosis with and without optic neuritis
  189. Neurofilament heavy chain as a marker of neuroaxonal pathology and prognosis in acute encephalitis
  190. Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients
  191. Neuro-Ophthalmic Literature Review
  192. Recurrent Optic Perineuritis after Intranasal Cocaine Abuse
  193. Biomarker time out
  194. The Clinical Spectrum of Microcystic Macular Edema
  195. Distribution of Retinal Layer Atrophy in Patients With Parkinson Disease and Association With Disease Severity and Duration
  196. A dam for retrograde axonal degeneration in multiple sclerosis?
  197. Disease course heterogeneity and OCT in multiple sclerosis
  198. Retinal hyperaemia-related blood vessel artifacts are relevant to automated OCT layer segmentation
  199. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study
  200. Neurodegeneration and Multiple Sclerosis
  201. Optical Coherence Tomography to Assess Neurodegeneration in Multiple Sclerosis
  202. Optic Neuritis: Another Dickensian Diagnosis
  203. Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids and Fatal B-Cell Lymphoma—Reply
  204. Physiological variation of segmented OCT retinal layer thicknesses is short-lasting
  205. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
  206. Should CLIPPERS Be Considered a Prelymphoma State or a New Inflammatory Disease?—Reply
  207. Intrathecal oligoclonal IgG synthesis in multiple sclerosis
  208. Pain Management in Neurocritical Care
  209. Fatal B-cell Lymphoma Following Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids
  210. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis
  211. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome
  212. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported
  213. Influence of the Eye-Tracking–Based Follow-Up Function in Retinal Nerve Fiber Layer Thickness Using Fourier-Domain Optical Coherence Tomography
  214. Patterns of non-embolic transient monocular visual field loss
  215. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis
  216. Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis
  217. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
  218. Embolic and Nonembolic Transient Monocular Visual Field Loss: A Clinicopathologic Review
  219. A Simple Sign for Recognizing Off–Axis OCT Measurement Beam Placement in the Context of Multicentre Studies
  220. Microcystic macular oedema in MS: T2 lesion or black hole?
  221. Comment on "Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model"
  222. Microcystic macular oedema confirmed, but not specific for multiple sclerosis
  223. Plasma Neurofilament Heavy Chain Levels Correlate to Markers of Late Stage Disease Progression and Treatment Response in SOD1G93A Mice that Model ALS
  224. Recurrent Laughter-induced Syncope
  225. Biomarkers of Disease Progression
  226. Serum GFAP levels in optic neuropathies
  227. Glial S100B is elevated in serum across the spectrum of west nile virus infection
  228. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment
  229. Neurofilament heavy chain and heat shock protein 70 as markers of seizure-related brain injury
  230. The Physiological Variation of the Retinal Nerve Fiber Layer Thickness and Macular Volume in Humans as Assessed by Spectral Domain–Optical Coherence Tomography
  231. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
  232. The Diagnostic and Prognostic Value of Neurofilament Heavy Chain Levels in Immune-Mediated Optic Neuropathies
  233. Serial soluble neurofilament heavy chain in plasma as a marker of brain injury after cardiac arrest
  234. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis
  235. Axonal damage in the making: Neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter
  236. Cerebrospinal Fluid Ferritin Level, a Sensitive Diagnostic Test in Late-Presenting Subarachnoid Hemorrhage
  237. The Prognostic Value of Brain Extracellular Fluid Nitric Oxide Metabolites After Traumatic Brain Injury
  238. Erratum to: Rostrocaudal Dynamics of CSF Biomarkers
  239. Disease-Specific Cerebrospinal Fluid Investigations
  240. The Use of Serum Glial Fibrillary Acidic Protein Measurements in the Diagnosis of Neuromyelitis Optica Spectrum Optic Neuritis
  241. Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis
  242. Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure
  243. Hyperacute Detection of Neurofilament Heavy Chain in Serum Following Stroke: A Transient Sign
  244. Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus
  245. Exceptional preservation of a prehistoric human brain from Heslington, Yorkshire, UK
  246. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease
  247. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
  248. The neurofilament light chain is not stable in vitro
  249. Reply
  250. What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 1: acute and monophasic diseases
  251. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
  252. Remote Ischemic Preconditioning Protects the Brain Against Injury After Hypothermic Circulatory Arrest
  253. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament “hook” effect
  254. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study
  255. International Issues: The EAYNT
  256. Neurodegeneration in MS and NMO: The Eye and the Blood
  257. Matrix Metalloproteinases in Myasthenia Gravis
  258. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies
  259. Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation
  260. Rostrocaudal Dynamics of CSF Biomarkers
  261. Evidence for acute neurotoxicity after chemotherapy
  262. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency
  263. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration
  264. PONM06 Plasma neurofilament heavy chain levels as a disease biomarker in the SOD1 mouse model of amyotrophic lateral sclerosis
  265. Ocular Flutter Following Adenoviral Conjunctivitis in an Adult
  266. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis
  267. Anti-Heat Shock Protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome
  268. Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases
  269. Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis
  270. Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes
  271. An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels
  272. Liquordiagnostik bei CT-negativer Subarachnoidalblutung
  273. Cerebrospinal fluid ATP metabolites in multiple sclerosis
  274. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein
  275. Recurrent ptosis due to myopathy of the levator palpebrae superioris
  276. Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking
  277. Neurology training around the world: asking the trainees
  278. Neurofilament ELISA validation
  279. Short commentary on ‘a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking’
  280. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis
  281. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
  282. Synchronised Paroxysmal Ocular Tilt Reaction and Limb Dystonia
  283. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile Virus infection
  284. Synchronised Paroxysmal Ocular Tilt Reaction and Limb Dystonia
  285. A novel biomarker for retinal degeneration: vitreous body neurofilament proteins
  286. Cerebrospinal fluid biomarkers in multiple sclerosis
  287. The Longitudinal Profile of Bilirubin and Ferritin in the Cerebrospinal Fluid Following a Subarachnoid Hemorrhage: Diagnostic Implications
  288. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients
  289. The longitudinal profile of CSF markers during external lumbar drainage
  290. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome
  291. Improving the recovery of S100B protein in cerebral microdialysis: Implications for multimodal monitoring in neurocritical care
  292. EFNS guidelines on disease-specific CSF investigations
  293. The Value of the Serum Neurofilament Protein Heavy Chain as a Biomarker for Peri-operative Brain Injury After Carotid Endarterectomy
  294. Glial fibrillary acidic protein in Guillain-Barré syndrome: Methodological issues
  295. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
  296. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy
  297. The Historical Origin of the Pulfrich Effect: A Serendipitous Astronomic Observation at the Border of the Milky Way
  298. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?
  299. Isolated, relapsing and progressive demyelinating diseases of the central nervous system
  300. Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology
  301. Glial and Axonal Body Fluid Biomarkers Are Related to Infarct Volume, Severity, and Outcome
  302. Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study
  303. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis
  304. Marathon related death due to brainstem herniation in rehydration-related hyponatraemia: a case report
  305. Assessing visual fields for driving in patients with paracentral scotomata
  306. CSF biomarkers for improved prognostic accuracy in acute CNS disease
  307. Plasma neurofilament heavy chain levels in Huntington's disease
  308. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis
  309. High CSF neurofilament heavy chain levels in neuromyelitis optica
  310. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain
  311. CSF Neurofilaments in Frontotemporal Dementia Compared with Early Onset Alzheimer’s Disease and Controls
  312. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia
  313. H<sub>2</sub>O Coma
  314. Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients
  315. CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndrome
  316. Brain Extracellular Fluid Nitrite/Nitrate Levels after Traumatic Brain Injury are Related to Survival
  317. Early Identification of Secondary Brain Damage in Subarachnoid Hemorrhage: A Role for Glial Fibrillary Acidic Protein
  318. Axonal damage and outcome in subarachnoid haemorrhage
  319. The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers
  320. Clinical disorders affecting mesopic vision
  321. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis
  322. Intra-arterial papaverine used to treat cerebral vasospasm reduces brain oxygen
  323. Axonal damage markers in cerebrospinal fluid are increased in ALS
  324. Measurement of high affinity antibodies on antigen-immunoblots
  325. High Intracranial Pressure, Brain Herniation and Death in Cerebral Venous Thrombosis
  326. Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes
  327. Free phenytoin concentration measurement in brain extracellular fluid: a pilot study
  328. The Neurofilament Heavy Chain (NfH<sup>SMI35</sup>) in the Cerebrospinal Fluid Diagnosis of Alzheimer’s Disease
  329. Educational Approach on Stroke Training in Europe
  330. Spectrophotometry for Cerebrospinal Fluid Pigment Analysis
  331. Extracellular N‐acetylaspartate depletion in traumatic brain injury
  332. Amniotic fluid brain‐specific proteins are biomarkers for spinal cord injury in experimental myelomeningocele
  333. 4-Dihydromethyltrisporate dehydrogenase, an enzyme of the sex hormone pathway in Mucor mucedo, is constitutively transcribed but its activity is differently regulated in (+) and (−) mating types
  334. Optic flow induced nystagmus
  335. No evidence for MSRV viraemia and glial cell death in acute optic neuritis
  336. Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
  337. Critical Illness Brain Syndrome (CIBS): An Underestimated Entity?
  338. Why Human Color Vision Cannot Reliably Detect Cerebrospinal Fluid Xanthochromia
  339. Extracellular fluid S100B in the injured brain: a future surrogate marker of acute brain injury?
  340. The Bryan cervical disc prosthesis as an alternative to arthrodesis in the treatment of cervical spondylosis: 46 CONSECUTIVE CASES
  341. Decreased CSF hypocretin-1 (orexin-A) after acute haemorrhagic brain injury
  342. Axonal Pathology in Subarachnoid and Intracerebral Hemorrhage
  343. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study
  344. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis
  345. Central and Paracentral Visual Field Defects and Driving Abilities
  346. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis
  347. Spectrophotometry for Xanthochromia
  348. Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
  349. Axonal degeneration and inflammation in acute optic neuritis
  350. Transient monocular blindness: the controversial role of the ophthalmic artery
  351. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis
  352. Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage
  353. An ELISA for glial fibrillary acidic protein
  354. Temporal Alterations in Cerebrospinal Fluid Amyloid  -Protein and Apolipoprotein E After Subarachnoid Hemorrhage
  355. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage
  356. Alterations in Cerebrospinal Fluid Apolipoprotein E and Amyloid β -Protein after Traumatic Brain Injury
  357. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission
  358. Cerebrospinal fluid (CSF) and serum S100B: release and wash-out pattern
  359. A specific ELISA for measuring neurofilament heavy chain phosphoforms
  360. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
  361. Cerebrospinal fluid nitrite/nitrate predicts poor outcome in patients with subarachnoid hemorrhage (SAH)
  362. Quantification of neurodegeneration by measurement of brain-specific proteins
  363. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors
  364. Video Reconstruction of Vasospastic Transient Monocular Blindness
  365. Serum and urine nitrate and nitrite are not reliable indicators of intrathecal nitric oxide production in acute brain injury
  366. Cerebrospinal Fluid Apolipoprotein E Concentration Decreases after Traumatic Brain Injury
  367. Decreased Cerebrospinal Fluid Apolipoprotein E After Subarachnoid Hemorrhage: Correlation With Injury Severity and Clinical Outcome
  368. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy
  369. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease
  370. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: A pilot study
  371. Media Watch
  372. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
  373. Rapidly developing intimal fibrosis mimicking giant cell arteritis
  374. Dense Kayser-Fleischer ring in asymptomatic Wilson's disease (hepatolenticular degeneration)
  375. Relapsing intracranial Rosai-Dorfman disease
  376. Recurrent ptosis
  377. Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat
  378. Recurrent ptosis in an adult due to isolated paresis of the levator palpebrae superioris and M�ller?s muscle of unknown aetiology
  379. Repetitive cerebral bleeding in an adult with Klippel-Trénaunay Syndrome
  380. Failure to detect bitemporal field defects due to chiasmal compression on a screening perimetry protocol
  381. Reply
  382. Hue memory and discrimination in young children
  383. Biological Markers
  384. Neuronal Cell Death and Axonal Degeneration: Neurofilaments as Biomarkers